PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 8, Issue 11, Pages 1833
Publisher
MDPI AG
Online
2019-11-02
DOI
10.3390/jcm8111833
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy
- (2019) Weimin Wang et al. NATURE
- PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature
- (2018) Prerna Guleria et al. Annals of Diagnostic Pathology
- The Integrated Genomic Landscape of Thymic Epithelial Tumors
- (2018) Milan Radovich et al. CANCER CELL
- Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial
- (2018) Jinhyun Cho et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune checkpoint therapy in liver cancer
- (2018) Feng Xu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma
- (2018) Dwight Owen et al. Journal of Thoracic Oncology
- Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study
- (2018) Giuseppe Giaccone et al. LANCET ONCOLOGY
- Correlation between the Expression of PD-L1 and Clinicopathological Features in Patients with Thymic Epithelial Tumors
- (2018) Yanmei Chen et al. Biomed Research International
- Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy
- (2018) Alice Yu et al. PLoS One
- ITGAE Defines CD8+ Tumor-Infiltrating Lymphocytes Predicting a better Prognostic Survival in Colorectal Cancer
- (2018) Xiang Hu et al. EBioMedicine
- Clinicopathologic Features of Thymoma With the Expression of Programmed Death Ligand 1
- (2018) Shuhei Hakiri et al. ANNALS OF THORACIC SURGERY
- Nobel committee honors tumor immunologists
- (2018) Anand Rotte et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus
- (2017) Alberto M. Marchevsky et al. HUMAN PATHOLOGY
- Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
- (2017) Christopher R Heery et al. LANCET ONCOLOGY
- Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs)
- (2017) Marcello Tiseo et al. LUNG CANCER
- Expression of PD-1 and PD-L1 in thymic epithelial neoplasms
- (2017) Annikka Weissferdt et al. MODERN PATHOLOGY
- Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors
- (2017) Kathryn C. Arbour et al. PLoS One
- Clinicopathologic and Prognostic Implications of Programmed Death Ligand 1 Expression in Thymoma
- (2016) Shintaro Yokoyama et al. ANNALS OF THORACIC SURGERY
- Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
- (2016) Noboru Yamamoto et al. INVESTIGATIONAL NEW DRUGS
- Response to Pembrolizumab in a Patient with Relapsing Thymoma
- (2016) Thilo Zander et al. Journal of Thoracic Oncology
- The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets
- (2016) Franz Enkner et al. PATHOLOGY & ONCOLOGY RESEARCH
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- PD-L1 expression in human cancers and its association with clinical outcomes
- (2016) Jinming Yu et al. OncoTargets and Therapy
- Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases
- (2016) Yan Yang et al. Journal of Thoracic Disease
- Thymic Epithelial Tumors: Prognostic Determinants Among Clinical, Histopathologic, and Computed Tomography Findings
- (2015) Jung Won Moon et al. ANNALS OF THORACIC SURGERY
- Surgical treatment of thymoma: an 11-year experience with 761 patients
- (2015) Yang Zhao et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- The 2015 World Health Organization Classification of Lung Tumors
- (2015) William D. Travis et al. Journal of Thoracic Oncology
- Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors
- (2015) Sukhmani K. Padda et al. Journal of Thoracic Oncology
- The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes
- (2015) Alexander Marx et al. Journal of Thoracic Oncology
- Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma
- (2015) Yuki Katsuya et al. LUNG CANCER
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potential of New Therapies like Anti-PD1 in Kidney Cancer
- (2014) Anasuya Gunturi et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
- (2014) G. K. Philips et al. INTERNATIONAL IMMUNOLOGY
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging
- (2014) Anya M. Litvak et al. Journal of Thoracic Oncology
- ITMIG Consensus Statement on the Use of the WHO Histological Classification of Thymoma and Thymic Carcinoma: Refined Definitions, Histological Criteria, and Reporting
- (2014) Alexander Marx et al. Journal of Thoracic Oncology
- A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors
- (2014) Iacopo Petrini et al. NATURE GENETICS
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemotherapy Definitions and Policies for Thymic Malignancies
- (2011) Nicolas Girard et al. Journal of Thoracic Oncology
- Epidemiology of Thymoma and Associated Malignancies
- (2010) Eric A. Engels Journal of Thoracic Oncology
- The Role of Chemotherapy in Advanced Thymoma
- (2010) Jordan Schmitt et al. Journal of Thoracic Oncology
- Management of Stage I and II Thymoma
- (2010) Frank C. Detterbeck et al. Thoracic Surgery Clinics
- Thymoma and thymic carcinoma
- (2009) Federico Venuta et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started